The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gaynitdinova V.V.

I.M. Sechenov First Moscow State Medical University

Burdunina A.A.

I.M. Sechenov First Moscow State Medical University

Avdeev S.N.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Features of bone metabolism in patients with chronic obstructive pulmonary disease: regulatory mechanisms and markers of bone remodeling

Authors:

Gaynitdinova V.V., Burdunina A.A., Avdeev S.N.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2021;24(1): 104‑108

DOI: 10.17116/profmed202124011104

Read: 1467 times

Download PDF (RU)
Contact the author
Table of contents

FEATURES OF BONE METABOLISM IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: REGULATORY MECHANISMS AND MARKERS OF BONE REMODELING
FEATURES OF BONE METABOLISM IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: REGULATORY MECHANISMS AND MARKERS OF BONE REMODELING

To cite this article:

Gaynitdinova VV, Burdunina AA, Avdeev SN. Features of bone metabolism in patients with chronic obstructive pulmonary disease: regulatory mechanisms and markers of bone remodeling. Russian Journal of Preventive Medicine. 2021;24(1):104‑108. (In Russ.)
https://doi.org/10.17116/profmed202124011104

 
 
 
Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Addi­tional criteria to differentiate the chro­nic obstructive pulmonary disease exacerbation and acute deco­mpensated chro­nic heart failure. Russian Journal of Preventive Medi­cine. 2024;(11):102-107
The condition of bone tissue in patients with non-alcoholic fatty liver disease. Russian Journal of Preventive Medi­cine. 2025;(5):82-89
Clinical effi­cacy of vita­min D in the prevention of osteoporosis and fractures in elde­rly patients. Russian Journal of Preventive Medi­cine. 2025;(5):103-110
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Liver and bone in tandem: osteopenia as an inevitable companion to non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):40-50
Chro­nic obstructive pulmonary disease (COPD 2024). Clinical guidelines (short version). Journal of Respiratory Medi­cine. 2025;(2):5-16
Toba­cco smoking as a factor in the deve­lopment of COPD and pulmonary tube­rculosis. Journal of Respiratory Medi­cine. 2025;(2):45-50
Rese­rves for redu­cing exacerbations in patients with chro­nic obstructive pulmonary disease at a large indu­strial ente­rprise. Journal of Respiratory Medi­cine. 2025;(2):66-70
Prognostic factors for progression and risk chro­nic obstructive pulmonary disease adve­rse outcomes. Journal of Respiratory Medi­cine. 2025;(2):71-78
Vertebroplasty for pathological vertebral fracture with osteoporosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):67-76
Abstract:

Chronic obstructive pulmonary disease (COPD) is a disease characterized by persistent airflow restriction that usually progresses as a consequence of a chronic inflammatory response of the airways and lung tissue to inhaled damaging particles or gases. Exacerbations and comorbid conditions are an integral part of the disease and make a significant contribution to the clinical picture and prognosis. Osteoporosis is one of the major comorbidities of COPD. In this review, the mechanisms of regulation of bone tissue metabolism (the role of the RANK/RANKL/OPG cytokine system, Wnt/β-catenin signaling pathway, matrix metalloproteinases, leptin and adiponectin) and individual markers of bone tissue remodeling (pro-peptides of type I procollagen, collagen I breakdown products type, osteocalcin) in patients with COPD. The recognition of a complete pathophysiological picture of the mechanisms and development of the disease will allow choosing the most effective therapeutic tactics that would correspond to the modern concept of personalized medicine.

Keywords:

chronic obstructive pulmonary disease
osteoporosis
metabolism
markers of bone remodeling

Authors:

Gaynitdinova V.V.

I.M. Sechenov First Moscow State Medical University

Burdunina A.A.

I.M. Sechenov First Moscow State Medical University

Avdeev S.N.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Received:

21.03.2020

Accepted:

13.07.2020

Close metadata

References:

  1. Aysanov ZR, Avdeev SN, Arkhipov VV, Belevsky AS, Leshchenko IV, Ovcharenko SI, Shmelev EI, Chuchalin AG. National clinical guidelines for the diagnosis and treatment of COPD: an algorithm for making clinical decisions. Pulmonology. 2017;27(1):13-20. (In Russ). https://doi.org/10.18093/0869-0189-2017-27-1-13-20
  2. Aganov DS, Tyrenko VV, Tsygan EN, Toporkov MM, Bologov SG. The role of cytokine system RANKL/RANK/OPG in the regulation of bone metabolism. Genes & Cells. 2014;9(4):50-52. (In Russ.).
  3. Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB. American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Endocrine Practice. 2016;22(suppl 4):1-42.  https://doi.org/10.4158/EP161435.GL
  4. Sarkar M, Bhardwaj R, Madabhavi I, Khatana J. Osteoporosis in chronic obstructive pulmonary disease. Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine. 2015;9:5-21.  https://doi.org/10.4137/CCRPM.S22803
  5. Kochetkova EA, Volkova MV, Kotsyurby EA. Biochemical markers of bone tissue metabolism and their clinical value under chronic obstructive lungs disease. Pacific Medical Journal. 2003;4(14):64-67. (In Russ.).
  6. Baud’huin M, Duplomb L, Teletchea S, Lamoureux F, Ruiz-Velasco C, Maillasson M, Redini F, Heymann MF, Heymann D. Osteoprotegerin: multiple partners for multiple functions. Cytokine & Growth Factor Reviews. 2013;24(5):401-409.  https://doi.org/10.1016/j.cytogfr.2013.06.001
  7. Simonet W, Lacey D, Dunstan C, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309-319.  https://doi.org/10.1016/S0092-8674(00)80209-3
  8. Okazaki R, Watanabe R, Inoue D. Osteoporosis Associated with Chronic Obstructive Pulmonary Disease. Journal of Bone Metabolism. 2016;23(3):111-120.  https://doi.org/10.11005/jbm.2016.23.3.111
  9. Berglundh S, Malmgren L, Luthman H, McGuigan F, Akesson K. C-reactive protein, bone loss, fracture, and mortality in elderly women: a longitudinal study in the OPRA cohort. Osteoporosis International. 2015;26(2):727-735.  https://doi.org/10.1007/s00198-014-2951-7
  10. Ahmadi-Abhari S, Luben RN, Wareham NJ, Khaw KT. C-reactive protein and fracture risk: European prospective investigation into Cancer Norfolk Study. Bone. 2013;56(1):67-72.  https://doi.org/10.1016/j.bone.2013.05.009
  11. Théoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine & Growth Factor Reviews. 2004;15:457-475.  https://doi.org/10.1016/j.cytogfr.2004.06.004
  12. Hu X, Sun Y, Xu W, Lin T, Zeng H. Expression of RANKL by peripheral neutrophils and its association with bone mineral density in COPD. Respirology. 2017;22(1):126-132.  https://doi.org/10.1111/resp.12878
  13. Bai P, Sun Y, Jin J, Hou J, Li R, Zhang Q, Wang Y. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respiratory Research. 2011;12(1):157.  https://doi.org/10.1186/1465-9921-12-157
  14. Eagan TM, Ueland T, Wagner PD, Hardie JA, Mollnes TE, Damås JK, Aukrust P, Bakke PS. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort study. European Respiratory Journal. 2010;35(3):540-548.  https://doi.org/10.1183/09031936.00088209
  15. Ugay L, Kochetkova E, Nevzorova V, Maistrovskaia Y. Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease. Chinese Medical Journal. 2016;129(14):1696-1703. https://doi.org/10.4103/0366-6999.185857
  16. Zhang PF, Pan L, Luo ZY, Zhao HJ, Cai SX. Interrelationship of circulating matrix metalloproteinase-9, TNF-α, and OPG/RANK/RANKL systems in COPD patients with osteoporosis. COPD. 2013;10(6):650-656.  https://doi.org/10.3109/15412555.2013.813928
  17. Pobeha P, Petrasova D, Tkacova R, Joppa P. Circulatory osteoprotegerin is related to osteoporosis of the hip in patients with COPD. Respiratory Medicine. 2014;108(4):621-627.  https://doi.org/10.1016/j.rmed.2013.12.011
  18. Duckers JM, Evans BA, Fraser WD, Stone MD, Bolton CE, Shale DJ. Low bone mineral density in men with chronic obstructive pulmonary disease. Respiratory Research. 2011;12(1):101.  https://doi.org/10.1186/1465-9921-12-101
  19. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Developmental Cell. 2005;8(5):739-750.  https://doi.org/10.1016/j.devcel.2005.03.016
  20. Rodda SJ, McMahon AP. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006;133(16):3231-3244. https://doi.org/10.1242/dev.02480
  21. Belaya ZE, Rozhinskaya LY, Melnichenko GA, Solodovnikov AG, Dragunova NV, Iljin AV, Dzeranova LK, Dedov II. Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing’s syndrome. Osteoporosis International. 2013;24(8):2191-2199. https://doi.org/10.1007/s00198-013-2268-y
  22. Kneidinger N, Yildirim AÖ, Callegari J, Takenaka S, Stein MM, Dumitrascu R, Bohla A, Bracke KR, Morty RE, Brusselle GG, Schermuly RT, Eickelberg O, Königshoff M. Activation of the WNT/β-catenin pathway attenuates experimental emphysema. American Journal of Respiratory and Critical Care Medicine. 2011;183(6):723-733.  https://doi.org/10.1164/rccm.200910-1560OC
  23. Wang R, Ahmed J, Wang G, et al. Down-regulation of the canonical Wnt β-catenin pathway in the airway epithelium of healthy smokers and smokers with COPD. PLoS One. 2011;6(4):e14793. https://doi.org/10.1371/journal.pone.0014793
  24. Skronska-Wasek W, Mutze K, Baarsma HA, et al. Reduced Frizzled Receptor 4 Expression Prevents WNT/β-Catenin-driven Alveolar Lung Repair in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2017;196(2):172-185.  https://doi.org/10.1164/rccm.201605-0904OC
  25. Sng JJ, Prazakova S, Thomas PS, Herbert C.MMP-8, MMP-9 and Neutrophil Elastase in Peripheral Blood and Exhaled Breath Condensate in COPD. COPD. 2017;14(2):238-244.  https://doi.org/10.1080/15412555.2016.1249790
  26. Bolton CE, Stone MD, Edwards PH, Duckers JM, Evans WD, Shale DJ. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Chronic Respiratory Disease. 2009;6(2):81-87.  https://doi.org/10.1177/1479972309103131
  27. Kochetkova EA, Ugai LG, Maistrovskaya YV, Burya KA, Nevzorova VA. Role of matrix metalloproteinase-9 in the pathogenesis of osteoporosis in patients with chronic obstructive pulmonary disease. Terapevticheskii Arkhiv. 2012;84(8):37-40. (In Russ.).
  28. Ugay LG, Kochetkova EA, Nevzorova VA. Relation between the leptin and adiponectin and bone metabolism in chronic obstructive pulmonary disease. Far East Medical Journal. 2012;3:10-13. (In Russ.).
  29. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J. Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clinical Chemistry. 1996;42(6 Pt 1):947-954. 
  30. Linkhart SG, Linkhart TA, Taylor AK, Wergedal JE, Bettica P, Baylink DJ. Synthetic peptidebased immunoassay for amino-terminal propeptide of type I procollagen: application for evaluation of bone formation. Clinical Chemistry. 1993;39(11 Pt 1):2254-2258.
  31. Garnero P. Bone markers in osteoporosis. Current Osteoporosis Reports. 2009;7(3):84-90.  https://doi.org/10.1007/s11914-009-0014-3
  32. Mohamed Y, Haifa H, Datel O, Fadoua HN, Smeh BH, Mahbouba J, Saoussen Z, Bejia I, Mongi T, Mohamed FN, Naceur B. The role of biochemical markers of bone turnover in the diagnosis of osteoporosis and predicting fracture risk. La Tunisie médicale. 2014;92(5):304-310. 
  33. Povoroznyuk VV, Masik NP. Markery metabolizma kostnoj tkani i ih klinicheskoe znachenie pri hronicheskoj obstruktivnoj bolezni legkih. Zhurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta. 2013;2(42):65-68. (In Russ.).
  34. Lemeshevskaya SS, SHepel’kevich AP, Vasil’eva NA. Mineral’naya plotnost’ kosti u muzhchin s hronicheskoj obstruktivnoj bolezn’yu. Medicinskij zhurnal. 2012;3(41):143-148. (In Russ.).
  35. Lou H, Peng C, Chen Q. Clinical value of serum total P1NP, β-CTX and 25(OH)D3 detection in evaluating risks of fragile hip fracture in elderly patients with osteoporosis. Journal of Southern Medical University. 2012;32(9):1346-1349.
  36. Pobel EA, Bengus LM, Deduh NV. Markery kostnogo metabolizma pri srashchenii perelomov dlinnyh kostej. Osteoporoz i osteopatii. 2012;2:25-32. (In Russ.).
  37. Mardanova OA, Kokina NI, Sheptulina LL, Serova AG, Sokolina IA, Ivashkin VT. The differences of bone metabolism in males with chronic obstructive pulmonary disease and postmenopausal females. The Clinician. 2012;6(1):46-50. (In Russ.).
  38. Dvoreckij LI. Hronicheskaya obstruktivnaya bolezn’ lyogkih i osteoporoz. Russkij medicinskij zhurnal. 2004;12(14):821-827. (In Russ.).
  39. Dinc M, Tchugunova Y, Dinc S, Cinarli B, Atasever T, Oz M. Decreased osteocalcin levels in patients with chronic obstructive pulmonary disease using long-term inhaled beclomethasone dipropionate. Metabolism. 2001;50(11):1336-1339. https://doi.org/10.1053/meta.2001.27231
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.